Prof. Derralynn Hughes is Professor of Experimental Haematology at the University College London, Research and Development Clinical Director at the Royal Free London NHS Foundation Trust Group. She is co-clinical Director of the NCL Cancer Alliance.
She has clinical responsibilities in the area of Haematology and Lysosomal Storage Disorders. She directs the research programme in the LSD unit where interests include understanding the pathophysiology of phenotypic heterogeneity in Fabry Disease and bone related pathology in Gaucher disease and malignancy. Prof. Hughes is Principal Investigator of a number of clinical trials examining the efficacy of new agents in the treatment of Gaucher, Fabry, Pompe and MPS disorders including gene therapies. Particular interests relate to the clinical and biological effects of bone disease and malignancy in Gaucher disease and the effects of Fabry disease in women; developing access standards for diagnosis and therapy for rare disorders; reducing inequalities in time to diagnosis of rare disorders using AI/algorithms in primary care to suggest candidates for genomics; accelerating clinical research including gene therapy for rare disorders. She is an author of over 200 papers in the area of macrophage biology and Lysosomal Storage Disorders.
